Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29834195 | 0.78 | ADORA1 (0.41) | — | |
| SCHEMBL17417835 | 0.74 | ADORA1 (0.37) | — | |
| SCHEMBL15996151 | 0.72 | ADORA1 (0.35) | — | |
| SCHEMBL29834227 | 0.72 | ADORA1 (0.39) | — | |
| SCHEMBL8332514 | 0.69 | PRMT6 (0.33) | P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL30183593 | 0.68 | ADORA1 (0.32) | — | |
| SCHEMBL9354230 | 0.68 | MEN1 (0.38) | SMN1; SMN2RXFP1 | |
| SCHEMBL10481813 | 0.67 | ADORA1 (0.39) | P2RY12 | |
| SCHEMBL2483147 | 0.67 | TYMP (0.56) | P2RY12 | |
| SCHEMBL31645122 | 0.65 | ADORA1 (0.45) | P2RY2P2RY1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067964-B2 | Complex and method for enhancing nuclear delivery | OLIGOMER SCIENCES AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20110306138-A1 | COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | OLIGOMER SCIENCES AB (SE) | 2011-12-15 | — | — | US | disclosed |
| EP-2376518-A1 | A COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | Avaris AB (SE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071587-A1 | A COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | AVARIS AB (SE) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306138-A1 | COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | SNRPE, SNRPA, HNRNPH3 | P2RY12 4345/4885P2RY2 4315/4885P2RY1 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.